Agreed. It's crystal clear in the ann - Completion of recruitment for both the Phase 2 BTX 1702 rosacea study and the BTX 1204 canine
atopic dermatitis study remains on track for 2Q 2022 with data to follow. The fb wording isn't great and more 'open to interpretation'
Some may think I am nit picking here but I am keen to make sure we don't start expecting data when it's not due.
Given the time it will take to analyse and compile the reports I would think end of Q3 could be a reasonable time to receive results.
Ann: Appendix 4C - Quarterly, page-9
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.0¢ |
Change
0.015(4.76%) |
Mkt cap ! $597.3M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.5¢ | 32.3¢ | $1.265M | 3.862M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 129446 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 131308 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |